Skip to main content

Table 1 Patient characteristics in patients with LARC after NCRT

From: Worse treatment response to neoadjuvant chemoradiotherapy in young patients with locally advanced rectal cancer

Characteristics Young group (n = 75) Old group (n = 826) p value
Sex (%)    0.527
 Male 52 (69.3) 537 (65.0)  
 Female 23 (30.7) 289 (35.0)  
Age (years) 34.3 ± 4.1 58.1 ± 9.4 < 0.001
ASA score (%)    < 0.001
 1 75 (100) 603 (73.0)  
 2 0 209 (25.3)  
 3 0 14 (1.6)  
Distance from the anal verge (cm) 6.4 ± 2.5 6.3 ± 2.3 0.684
Time interval between CRT and surgery (weeks) 9.1 ± 1.4 9.4 ± 2.9 0.468
Clinical T stage (%)    0.173
 T1 1 (1.3) 2 (0.2)  
 T2 0 18 (2.2)  
 T3 25 (33.3) 317 (38.4)  
 T4 49 (65.3) 489 (59.7)  
Clinical N stage (%)    1.000
 N0 7 (9.3) 79 (9.5)  
 N+ 68 (90.7) 747 (90.5)  
Pre-NCRT CEA level (%)    0.562
  < 5.0 ng/ml 25(33.3) 283 (34.3)  
  ≥ 5.0 ng/ml 24(32.0) 219 (26.5)  
 Unknown 26(34.7) 324 (39.2)  
Pre-NCRT CA19–9 level (%)    0.641
  < 39.0 U/ml 40 (53.3) 430 (52.1)  
  ≥ 39.0 U/ml 9 (12.0) 76 (9.2)  
 Unknown 26(34.7) 320 (38.7)  
Post-NCRT CEA level (%)    0.115
  < 5.0 ng/ml 67 (89.3) 672 (81.4)  
  ≥ 5.0 ng/ml 8 (10.7) 154 (18.6)  
Post-NCRT CA19–9 level (%)    0.320
  < 39.0 U/ml 68 (90.7) 775 (93.8)  
  ≥ 39.0 U/ml 7 (9.3) 51 (6.2)  
  1. LARC Locally advanced rectal cancer; NCRT Neoadjuvant chemoradiotherapy; ASA American Society of Anesthesiologists; CRT Chemoradiotherapy; CEA Carcinoembryonic Antigen; CA19–9 Carbohydrate Antigen 19–9